A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Public ClinicalTrials.gov record NCT07690371. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as compared to placebo. The estimated participant overall duration is approximately 15 months.
Study identification
- NCT ID
- NCT07690371
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 510 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 28, 2026
- Primary completion
- Apr 30, 2028
- Completion
- Nov 30, 2028
- Last update posted
- Aug 3, 2026
2026 – 2028
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Nektar Investigative Site | Fountain Valley | California | 92708-3701 | Recruiting |
| Nektar Investigative Site | Los Angeles | California | 90025-7014 | Recruiting |
| Nektar Investigative Site | Boca Raton | Florida | 33486 | Recruiting |
| Nektar Investigative Site | St. Petersburg | Florida | 33714 | Recruiting |
| Nektar Investigative Site | Macon | Georgia | 31217-3865 | Recruiting |
| Nektar Investigative Site | Normal | Illinois | 61761-6280 | Recruiting |
| Nektar Investigative Site | Bowling Green | Kentucky | 42104 | Recruiting |
| Nektar Investigative Site | Owensboro | Kentucky | 42301 | Recruiting |
| Nektar Investigative Site | Lafayette | Louisiana | 70508 | Recruiting |
| Nektar Investigative Site | Omaha | Nebraska | 68144-5604 | Recruiting |
| Nektar Investigative Site | Clifton | New Jersey | 07013 | Recruiting |
| Nektar Investigative Site | New York | New York | 10023 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07690371, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 3, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07690371 live on ClinicalTrials.gov.